#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Philadelphia positive chronic myeloid leukaemia Malignant oligodendroglioma Rheumatoid arthritis Pulmonary hypertension Dementia Alzheimer's type Familial hypertriglyceridaemia Activated PI3 kinase delta syndrome Deafness Duchenne muscular dystrophy gene carrier Hyperoxaluria Head and neck cancer Neurofibromatosis Cataract SAPHO syndrome Acute myeloid leukaemia (in remission) More trials…

    Learn about Rare Diseases

    Hereditary neuropathic amyloidosis – Life with Disease Tuberous sclerosis complex – Basic Information Leiomyosarcoma – Basic Information Ewing’s sarcoma metastatic – Diagnostics Rhabdomyosarcoma recurrent – Life with Disease Pemphigoid – Treatment Myelodysplastic syndrome with excess blasts – Basic Information Angelman’s syndrome – Treatment Acquired haemophilia – Life with Disease Hereditary neuropathic amyloidosis – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Fadraciclib Larotrectinib Sulfate Glucocorticoids Povorcitinib Maridebart Cafraglutide XENON (133XE) Sodium Lactate IDROXIOLEIC ACID Ivacaftor Betula Alba Pollen Extract Fludarabine Mecillinam Ribitol PETHIDINE HYDROCHLORIDE Maraviroc Methoxsalen Fluindione ADX-038 Deutivacaftor Fludarabine Phosphate More therapies…

    Learn about Your Condition

    Endotracheal intubation Hypocalcaemia Infertility female Apathy Salivary gland cancer Primary hyperthyroidism Follicular lymphoma stage II BRAF gene mutation Amyloidosis K-ras gene mutation Bronchostenosis Sickle cell disease Bladder cancer recurrent Gestational diabetes Neuropathic arthropathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2eq Buiwqeisq Dh Sdplmd Mtvpojzhxza Bo 1ttb Mvpnikhmiz 1laihs Firapf

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Bortezomib
    • Dexamethasone
    • Dexamethasone Ph. Eur.
    Austria Belgium Czechia Denmark France Germany +7

  • Study comparing brigatinib alone versus brigatinib with carboplatin and pemetrexed combination as first treatment for patients with advanced ALK-positive lung cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage IIIB
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Brigatinib
    • Carboplatin
    • Pemetrexed
    France

  • Study of ALX148 with Trastuzumab, Ramucirumab, and Paclitaxel for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

    Not recruiting

    4 1 1
    Investigated Drugs:
    • Paclitaxel
    • Ramucirumab
    • Trastuzumab
    Belgium Czechia France Italy Spain

  • Study of Daratumumab with Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Eligible for High-Dose Therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Bortezomib
    • Daratumumab
    • Dexamethasone Acetate
    Belgium Czechia Denmark France Germany Greece +5

  • Study on Nivolumab and Ipilimumab for Patients with Untreated Unresectable or Metastatic Urothelial Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Gemcitabine
    Czechia Denmark France Germany Greece Italy +5

  • Study of SAR443579 Infusion for Adults and Children with Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, HR-MDS, or BPDCN

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Blastic plasmacytoid dendritic cell neoplasia
    • Acute myeloid leukaemia refractory
    • B-cell type acute leukaemia
    Investigated Drugs:
    • Chlorphenamine Maleate
    • Dextromethorphan Hydrobromide
    • Sar-443579
    France The Netherlands

  • Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Epirubicin
    • Doxorubicin
    • Capecitabine
    Austria Belgium Bulgaria France Germany Hungary +3

  • Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Olaparib
    Austria Belgium France Germany Hungary Iceland +6

  • Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • 3-[6-(1-Benzylpiperidin-4-Yl)-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione
    • Canakinumab
    • Heterodimeric Interleukin-15
    Belgium Czechia France Germany Hungary Italy +2

  • Study on the Safety and Effects of IPH6501 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

    Not recruiting

    1 1 1
    Investigated Drugs:
    • Iph6501
    France
Previous Page
1 … 30 31 32 33 34 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!